Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Cyclooxygenase-2 (COX-2), officially designated prostaglandin-endoperoxide synthase 2 (PTGS2), is an inducible enzyme found in the central nervous system that catalyzes the conversion of arachidonic acid to prostaglandins, particularly prostaglandin E2 (PGE2).[1][6] In the brain, COX-2 is constitutively expressed in glutamatergic neurons of the cerebral cortex, hippocampus, and amygdala, and becomes further upregulated in response to inflammatory stimuli, cytokines, seizure activity, and neuronal activation.[1][2][4] COX-2 plays a critical physiological role in synaptic transmission, long-term potentiation, memory consolidation, and neural plasticity through its production of PGE2 and its interactions with endocannabinoid signaling.[1][2] However, excessive COX-2 expression and activity contribute to neuropathology in multiple neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, multiple sclerosis, and in acute conditions such as traumatic brain injury and stroke-induced ischemia, primarily through enhanced glutamate excitotoxicity and neuroinflammation.[1][2][4] COX-2 is a validated therapeutic target; selective COX-2 inhibitors such as celecoxib and other NSAIDs reduce neuroinflammation and provide neuroprotection in animal models, though their clinical use remains complicated by cardiovascular and gastrointestinal safety concerns and the need to preserve COX-2's normal physiological functions in memory and cognition.[2][3][4]
NSAIDs and selective COX-2 inhibitors block COX-2 catalytic activity, thereby reducing the conversion of arachidonic acid to prostaglandins and subsequently decreasing the production of prostaglandin E2. This enzyme inhibition suppresses excessive excitatory glutamatergic neurotransmission, enhances endocannabinoid signaling by preventing their metabolism, reduces neuroinflammation by inhibiting microglial activation, and prevents neuronal excitotoxicity.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cyclooxygenase-2 (COX-2) in the Central Nervous System (COX-2).